Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
Is Shorter Dual Antiplatelet Therapy Safe for Newer
Complex Coronary Cases - ppt download
Synergy: Short DAPT Study - ppt download
Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science | tctmd.com
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
Can We Define High-risk DAPT Patients in USA Practice? - ppt download
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Two further studies support three-month DAPT following PCI
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
